INVALID TRIAL
CHIA and your personal trial have no criteria in common

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤═════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria           │   Score │
╞════════════════════════════════════════════════════╪═════════════════════════╪═════════╡
│ females who are sexually active refusing to use    │ Stage IA or IIA disease │      13 │
│ effective contraception (oral contraception,       │                         │         │
│ intrauterine devices, barrier method of            │                         │         │
│ contraception in conjunction with spermicidal      │                         │         │
│ jelly or surgical sterile) (except for surgery     │                         │         │
│ only)                                              │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ Current or recent (within 30 days prior to the     │ No prior therapy        │      15 │
│ start of trial treatment) treatment with another   │                         │         │
│ investigational drug or participation in another   │                         │         │
│ investigational trial                              │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ initial stage IA/IIA (according to local staging)  │ Stage IA or IIA disease │      20 │
│ or relapse stage IA or IIA and residual tumour     │                         │         │
│ after relapse biopsy and no additional surgery     │                         │         │
│ planned in nLP patients relapsing after surgery    │                         │         │
│ alone                                              │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ written informed consent of the patient and/or the │ Stage IA or IIA disease │      20 │
│ patient's parents or guardian according to         │                         │         │
│ national laws                                      │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ Inability to fulfil protocol requirements for      │ Stage IA or IIA disease │      22 │
│ imaging (CT, MRI, FDG-PET) at staging and response │                         │         │
│ assessment                                         │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ nodular lymphocyte-predominant Hodgkin's lymphoma  │ No prior therapy        │      24 │
│ confirmed by reference pathology                   │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ Current or recent therapy (within 30 days prior to │ No prior therapy        │      24 │
│ the start of trial treatment) with steroids        │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ pre-treatment of Hodgkin's lymphoma differing from │ Stage IA or IIA disease │      27 │
│ study protocol                                     │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ severe concomitant diseases (e.g. immune           │ Not specified           │      27 │
│ deficiency syndrome)                               │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ Any extra-nodal involvement                        │ Stage IA or IIA disease │      28 │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ pregnancy and / or lactation                       │ No prior therapy        │      32 │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ known hypersensitivity or contraindication to      │ No prior therapy        │      33 │
│ study drugs                                        │                         │         │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ known HIV positivity                               │ No prior therapy        │      33 │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ other (simultaneous) malignancies                  │ Not specified           │      35 │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ patient aged under 18 years at time of diagnosis   │ Stage IA or IIA disease │      37 │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ Must have maximum age of 17 Years                  │ Stage IA or IIA disease │      39 │
├────────────────────────────────────────────────────┼─────────────────────────┼─────────┤
│ prior chemotherapy or radiotherapy                 │ No prior therapy        │      52 │
╘════════════════════════════════════════════════════╧═════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════╤═════════════════════════╤═════════╕
│ Personal Criteria                  │ CHIA Criteria           │   Score │
╞════════════════════════════════════╪═════════════════════════╪═════════╡
│ other (simultaneous) malignancies  │ Not specified           │      35 │
├────────────────────────────────────┼─────────────────────────┼─────────┤
│ Must have maximum age of 17 Years  │ Stage IA or IIA disease │      39 │
├────────────────────────────────────┼─────────────────────────┼─────────┤
│ prior chemotherapy or radiotherapy │ No prior therapy        │      52 │
├────────────────────────────────────┼─────────────────────────┼─────────┤
│ Any extra-nodal involvement        │ NA                      │       7 │
╘════════════════════════════════════╧═════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 7
Average Levenshtein Ratio of individual lines: 29.238095238095237
OverAll Ratio: 18.11904761904762
